RSS

NeoPhore

Cancer immune-oncology company, NeoPhore, and developer of a next-generation phenotypic screening platform, PhoreMost, have been granted funding from Innovate UK in support of the development of novel small-molecule cancer immunotherapy programme. more

News

UK based fund manager, Sixth Element Capital, has announced a £3 million investment in a spin out company from PhoreMost — NeoPhore. more

News